Comparing of IMV Inc. (IMV) and uniQure N.V. (NASDAQ:QURE)

Both IMV Inc. (NASDAQ:IMV) and uniQure N.V. (NASDAQ:QURE) are Biotechnology companies, competing one another. We will compare their institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
IMV Inc. 4 0.00 N/A -0.34 0.00
uniQure N.V. 54 275.12 N/A -2.48 0.00

Table 1 demonstrates IMV Inc. and uniQure N.V.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 provides us IMV Inc. and uniQure N.V.’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
IMV Inc. 0.00% 0% 0%
uniQure N.V. 0.00% -48.9% -32.6%

Analyst Ratings

IMV Inc. and uniQure N.V. Recommendations and Ratings are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
IMV Inc. 0 0 2 3.00
uniQure N.V. 0 0 8 3.00

IMV Inc.’s upside potential is 262.90% at a $11.25 average price target. Competitively the average price target of uniQure N.V. is $81, which is potential 17.99% upside. The results from earlier shows that analysts view suggest that IMV Inc. seems more appealing than uniQure N.V.

Institutional and Insider Ownership

Institutional investors held 19.5% of IMV Inc. shares and 73.8% of uniQure N.V. shares. 16.5% are IMV Inc.’s share held by insiders. On the other hand, insiders held about 1.9% of uniQure N.V.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
IMV Inc. -7.05% 27.41% -18.2% -27.72% -17.69% -20.89%
uniQure N.V. -0.41% 2.94% 58.22% 127.49% 81.88% 103.02%

For the past year IMV Inc. had bearish trend while uniQure N.V. had bullish trend.

IMV Inc., a clinical-stage company, together with its subsidiaries, develops products based on its platform and products with a primary focus on T cell activating therapies for cancer. The company's DepoVax platform is a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. It has two T cell activation therapies for cancer through Phase I human clinical trial and is conducting a Phase Ib study with Incyte Corporation for lead cancer therapy; and DPX-Survivac, as a combination therapy for ovarian cancer. The company is also conducting a Phase II study for DPX-Survivac in ovarian and lymphoma. In addition, it is developing DPX-RSV, a vaccine candidate, which has completed a Phase I clinical trial for respiratory syncytial virus, as well as has clinical projects to assess the DepoVax to address malaria and the Zika virus; DPX-E7 an investigational immunotherapy that targets a viral protein in human papillomavirus (HPV) known as E7. The company has research collaborations with companies and research organizations, including Merck, Incyte Corporation, and Leidos Inc, as well as with Zoetis. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is based in Halifax, Canada.

uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The companyÂ’s principle programs include AMT-060, a gene therapy that has completed Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical product candidate for the treatment of congestive heart failure; and AMT-130 for the treatment of huntington's disease. It also provides Glybera, a gene therapy product that has approved for the treatment of patients with lipoprotein lipase deficiency. The company has collaboration and license agreements with Bristol-Myers Squibb Company, 4D Molecular Therapeutics, Synpromics, and Chiesi Farmaceutici S.p.A. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.